Director/PDMR Shareholding

18 Jul 2007 07:01

Akers Biosciences, Inc.18 July 2007 Embargoed: 0700hrs 18 July 2007 Akers Biosciences, Inc. ("ABI" or the "Company") Directors Shareholding & Additional Listing Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, pointof care screening and testing products announces that several of its directorshave, on 17 July 2007, increased their shareholdings in the Company by way of asubscription to New Ordinary shares. Every member of the board has now, sincethe publication of the Company's financial results on 26 June 2007, eitherinvested in the Company via the purchase of shares or converted their fees intoshares. David Wilbraham has invested £25,000 by way of a subscription to 250,000 NewOrdinary Shares at yesterday's closing price of 10 pence. Mr. Wilbraham'sshareholdings now total 868,000 common shares, representing 1.36% of the totalissued share capital of the Company. Dr. Raymond Akers has invested $130,000 by way of a subscription to 635,697 NewOrdinary Shares at yesterday's closing price of 10 pence. Dr. Akers'shareholdings, including his immediate family, now total 7,902,702 commonshares, representing 12.42% of the total issued share capital of the Company. Thomas A. Nicolette has converted $16,875 of fees into 82,518 New OrdinaryShares at yesterday's closing price of 10 pence. Mr. Nicolette's shareholdingsnow total 656,017 common shares, representing 1.03% of the total issued sharecapital of the Company. Edward Wampold has converted $14,600 of fees into 71,394 New Ordinary Shares atyesterday's closing price of 10 pence. Mr. Wampold's shareholdings now total249,394 common shares, representing 0.39% of the total issued share capital ofthe Company. Daniel Seckinger, MD has converted $30,000 of fees into 146,699 New OrdinaryShares at yesterday's closing price of 10 pence. Dr. Seckinger's shareholdingsnow total 514,888 common shares, representing 0.8% of the total issued sharecapital of the Company. The Company has also issued 184,350 New Ordinary Shares to an advisor in lieu offees. Application has been made to the London Stock Exchange for 1,370,658 NewOrdinary Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to trading, such admission expected to take place on 23 July 2007. The exchange rate used for these transactions was $2.045:£1.00. Enquiries: Thomas A. Nicolette, President & CFOAkers Biosciences, Inc.Tel. 001 856 848 8698 Ben SimonsHansard GroupTel. 020 7245 1100 Xavier de MolBridgewellTel. 020 7003 3000 This information is provided by RNS The company news service from the London Stock Exchange